Moshe Phillip

Institute of Endocrinology & Diabetes engages in medical services. The company is headquartered in Westmead, Australia.

DreaMed Diabetes Ltd. is a medical technology company based in Petach Tikva, Israel. DreaMed Diabetes is currently commercializing its endo.digital AI-based clinical decision support system for diabetes management. The endo.digital platform has FDA clearance for patients with type 1 diabetes using continuous glucose monitors or self-monitoring blood glucose monitor devices and insulin pumps. The technology also received expanded FDA clearance to include patients with type 1 or type 2 diabetes on multiple daily injections. The Israeli company's first product, an artificial pancreas technology, was licensed to Medtronic and incorporated into its 780g insulin pump technology. The company provides personalized diabetes treatment optimization solutions and was founded in 2014 by Revital Nimri, Tadej Battelino, Eran Atlas, Thomas Danne, and Ido Muller. Eran Atlas has been the CEO since 2014.

Medicine On Line Israel (Moli) Ltd. is engaged in the field of diabetes . It focuses on: Improving the quality of life and medical treatment for people with diabetes, Performing educational activities, Producing scientific publications, and training people with diabetes. The association was founded by Ludwig Nelken, Herman Wolfson, Dr Liven, and Prof. A. M. Cohen in 1954 and is headquartered in Rishon Le-Zion, Israel.

Part of Elliott International Advisors GP LLC, Continuing Medical Education, Inc. publishes medical magazines and journals. The private company is based in San Diego, CA. Continuing Medical Education was acquired by Miller Freeman, Inc., part of Elliott International Advisors GP LLC from July 18, 2000 on March 26, 1999 for $111 million.

C.G.M.3 Ltd is an early-stage medical company that was founded in 2007 and joined NAIOT Venture Accelerator, at Yokneam, Israel in 2009, as a seed company. C.G.M.3 Ltd is developing a miniaturized implantable device which utilizes a groundbreaking solution for reliable, real- time, long-term Continuous Glucose Monitoring (CGM). The device will ultimately offer a true resolution and improved quality of life for diabetes patients. In fact, C.G.M.3 solution presents the missing link towards a potent closed-loop artificial pancreas.